Loading...

APC anti-human CD45RA Antibody

Pricing & Availability
Clone
HI100 (See other available formats)
Regulatory Status
RUO
Workshop
IV N906
Other Names
GP180, L-CA, LCA, LY5, T200, PTPRC
Isotype
Mouse IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
HI100_APC_062707
Human peripheral blood lymphocytes stained with HI100 APC
  • HI100_APC_062707
    Human peripheral blood lymphocytes stained with HI100 APC
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
304111 25 tests 55 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
304112 100 tests 132 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
304150 100 µg 137 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45RA is a 205-220 kD single chain type I glycoprotein. It is an exon 4 splice variant of the tyrosine phosphatase CD45. The CD45RA isoform is expressed on resting/naïve T cells, medullary thymocytes, B cells and monocytes. CD45RA enhances both T cell receptor and B cell receptor signaling. CD45 non-covalently associates with lymphocyte phosphatase-associated phosphoprotein (LPAP) on T and B lymphocytes. CD45 has been reported to be associated with several other cell surface antigens including CD1, CD2, CD3, and CD4. CD45 has also been reported to bind galectin-1. CD45 isoform expression can change in response to cytokines.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
µg size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
test sizes: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
test sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. For flow cytometric staining using the test sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for relevant formats of this clone) include: inhibition of CD45 functions2, immunohistochemical staining of frozen tissue sections3 and formalin-fixed paraffin-embedded tissue sections4, and immunocytochemistry15,16.

Application References

(PubMed link indicates BioLegend citation)
  1. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Yamada T, et al. 2002. J. Biol. Chem. 277:28830. (WB, Block)
  3. Weninger W, et al. 2003 J. Immunol. 170:4638. (IHC-F)
  4. Imanguli MM, et al. 2009. Blood. 113:3620 (IHC-P)
  5. Roque S, et al. 2007. J. Immunol. 178:8028. (FC) PubMed
  6. Smeltz RB. 2007. J. Immunol. 178:4786. (FC) PubMed
  7. Palendira U, et al. 2008. Blood (FC) PubMed
  8. Kuttruff S, et al. 2009. Blood 113:358. (FC) PubMed
  9. Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
  10. Alanio C, et al. 2010. Blood 115:3718. (FC) PubMed
  11. Iannello A, et al. 2010. J. Immunol. 184:114. (FC) PubMed
  12. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  13. Guereau-de-Arellan M, et al. 2011. Brain. 134:3578. PubMed
  14. Canque B, et al. 2000. Blood 96:3748. (ICC)
  15. Imanguli MM, et al. 2009. Blood 13:3620. (ICC)
  16. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
  17. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
Product Citations
  1. Aschmoneit N, et al. 2021. J Immunother Cancer. 9:. PubMed
  2. Cox MJ, et al. 2022. Leukemia. 36:1635. PubMed
  3. Omer-Javed A, et al. 2022. Cell. 185:2248. PubMed
  4. Balta E, et al. 2023. Front Immunol. 13:1063313. PubMed
  5. Ye L, et al. 2022. Cell Metab. 34:595. PubMed
  6. Yen M, et al. 2022. Cell. 185:1414. PubMed
  7. Ivan Jelcic et al. 2018. Cell. 175(1):85-100 . PubMed
  8. Huang X, et al. 2021. Nat Nanotechnol. 16:214. PubMed
  9. Sinnott B, et al. 2016. J Immunol. 197: 68 - 77. PubMed
  10. Xiao C, et al. 2022. iScience. 25:103934. PubMed
  11. Du L, et al. 2021. Front Mol Biosci. 8:675179. PubMed
  12. Wu K, et al. 2021. Aging (Albany NY). 13:. PubMed
  13. Kobayashi Y, et al. 2020. Int J Oncol. 999:56. PubMed
  14. Wang J, et al. 2020. Cell. 183:1264. PubMed
  15. Beatson RE, et al. 2021. Cell Rep Med. 2:100473. PubMed
  16. Naaber P, et al. 2022. Cell Rep Med. 3:100716. PubMed
  17. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  18. Wu D, et al. 2020. Biomark Res. 8:3. PubMed
  19. Aschmoneit N, et al. 2022. Oncoimmunology. 11:2028961. PubMed
  20. Locke F, et al. 2017. Mol Ther. 25(1):285-295. PubMed
  21. Seumois G, et al. 2016. J Immunol. 197: 655 - 664. PubMed
  22. Hebbar N, et al. 2022. Nat Commun. 13:587. PubMed
  23. Stunnenberg M, et al. 2020. Viruses. 12:00. PubMed
  24. Hazeldine J, et al. 2017. PLoS Med. 10.1371/journal.pmed.1002338. PubMed
  25. Wu J et al. 2019. Immunity. 50(5):1218-1231 . PubMed
  26. Aschmoneit N, et al. 2021. Sci Rep. 11:13880. PubMed
  27. Kim Y, et al. 2015. Blood. 125:1107. PubMed
  28. Tomalka J, Jesus T, Ramakrishnan P 2016. J Leukoc Biol. 100: 111 - 120. PubMed
  29. Gawel DR, et al. 2019. Genome Med. 11:47. PubMed
  30. Christiansen M, et al. 2020. Front Immunol. 10:3022. PubMed
  31. Bonte S, et al. 2021. Oncoimmunology. 10:1954800. PubMed
  32. Li Z, et al. 2014. PLoS One. 9:106064. PubMed
  33. Thomas R, et al. 2020. Cancer Immunol Immunother. 69:449. PubMed
  34. Dai Z, et al. 2022. Signal Transduct Target Ther. 7:85. PubMed
  35. Qin H, et al. 2015. Blood. 126: 629 - 639. PubMed
  36. Xie G, et al. 2021. Cell Reports. 35(4):109038. PubMed
  37. Rousso-Noori L, et al. 2021. Nat Commun. 12:3615. PubMed
  38. Yazdani S, et al. 2022. Nat Commun. 13:6733. PubMed
  39. Wang B, et al. 2018. Mol Ther Nucleic Acids. 0.548611111. PubMed
  40. Wu B, et al. 2022. Nat Commun. 13:2155. PubMed
  41. Corrado M, et al. 2020. Cell Metab. 32:981. PubMed
  42. Mesquitta WT, et al. 2019. Sci Rep. 4.973611111. PubMed
  43. Ribot J, et al. 2014. J Immunol. 192:2237. PubMed
RRID
AB_2564158 (BioLegend Cat. No. 304111)
AB_2564158 (BioLegend Cat. No. 304112)
AB_2564158 (BioLegend Cat. No. 304150)

Antigen Details

Structure
Tyrosine phosphatases, type I transmembrane (exon 4 splicing of CD45 gene), 205-220 kD
Distribution

B cells, naïve T cells, monocytes

Function
Enhances TCR and BCR signaling
Ligand/Receptor
Galectin-1, CD2, CD3, CD4
Cell Type
B cells, Monocytes, T cells, Tregs
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules
Antigen References

1. Thomas M. 1989. Annu. Rev. Immunol. 7:339.
2. Trowbridge I, et al. 1994. Annu. Rev. Immunol.12:85.

Gene ID
5788 View all products for this Gene ID
UniProt
View information about CD45RA on UniProt.org

Other Formats

View All CD45RA Reagents Request Custom Conjugation
Description Clone Applications
APC anti-human CD45RA HI100 FC
Biotin anti-human CD45RA HI100 FC
FITC anti-human CD45RA HI100 FC
PE anti-human CD45RA HI100 FC,SB
PE/Cyanine5 anti-human CD45RA HI100 FC
Purified anti-human CD45RA HI100 FC,CyTOF®,ICC,IHC-P,IHC-F,SB
Alexa Fluor® 488 anti-human CD45RA HI100 FC
Alexa Fluor® 647 anti-human CD45RA HI100 FC,IHC-P
Pacific Blue™ anti-human CD45RA HI100 FC
Alexa Fluor® 700 anti-human CD45RA HI100 FC
PerCP/Cyanine5.5 anti-human CD45RA HI100 FC,SB
PE/Cyanine7 anti-human CD45RA HI100 FC
APC/Cyanine7 anti-human CD45RA HI100 FC
Brilliant Violet 421™ anti-human CD45RA HI100 FC,IHC-P
Brilliant Violet 570™ anti-human CD45RA HI100 FC
Brilliant Violet 605™ anti-human CD45RA HI100 FC
Brilliant Violet 650™ anti-human CD45RA HI100 FC
Brilliant Violet 711™ anti-human CD45RA HI100 FC
Brilliant Violet 785™ anti-human CD45RA HI100 FC
Brilliant Violet 510™ anti-human CD45RA HI100 FC
Purified anti-human CD45RA (Maxpar® Ready) HI100 FC,CyTOF®
PE/Dazzle™ 594 anti-human CD45RA HI100 FC
APC/Fire™ 750 anti-human CD45RA HI100 FC
PerCP anti-human CD45RA HI100 FC
FITC anti-human CD45RA HI100 FC
TotalSeq™-A0063 anti-human CD45RA HI100 PG
Alexa Fluor® 594 anti-human CD45RA HI100 IHC-P
TotalSeq™-B0063 anti-human CD45RA HI100 PG
TotalSeq™-C0063 anti-human CD45RA HI100 PG
Brilliant Violet 750™ anti-human CD45RA HI100 FC
Spark NIR™ 685 anti-human CD45RA HI100 FC
APC anti-human CD45RA HI100 FC
PE/Fire™ 640 anti-human CD45RA HI100 FC
PE/Fire™ 700 anti-human CD45RA Antibody HI100 FC
Spark YG™ 581 anti-human CD45RA HI100 FC
TotalSeq™-D0063 anti-human CD45RA HI100 PG
Spark Violet™ 423 anti-human CD45RA HI100 FC,IHC-P
GMP FITC anti-human CD45RA HI100 FC
PE/Cyanine7 anti-human CD45RA HI100 FC
PE/Dazzle™ 594 anti-human CD45RA HI100 FC
APC/Fire™ 750 anti-human CD45RA HI100 FC
Spark UV™ 387 anti-human CD45RA HI100 FC
GMP APC anti-human CD45RA HI100 FC
TotalSeq™-Bn0063 anti-human CD45RA HI100 SB
Spark Blue™ 550 anti-human CD45RA HI100 FC
GMP PE/Dazzle™ 594 anti-human CD45RA HI100 FC
GMP APC/Fire™ 750 anti-human CD45RA HI100 FC
Spark PLUS UV395™ anti-human CD45RA HI100 FC
Spark Red™ 718 anti-human CD45RA HI100 FC
APC/Fire™ 810 anti-human CD45RA HI100 FC
PE/Fire™ 810 anti-human CD45RA HI100 FC
Spark Blue™ 574 anti-human CD45RA (Flexi-Fluor™) HI100 FC
Go To Top Version: 2    Revision Date: 07.25.2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account